The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Shuji Murakami
Honoraria - AstraZeneca; Chugai Pharma; Lilly O.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Janssen; Merck Sharp & Dohme; Ono Pharmaceutical; Sanofi; Takeda
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Kyoichi Okishio
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Nippon Kayaku; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
 
Motohiro Tamiya
Honoraria - Amgen; Asahi Kasei; AstraZeneca; Bayer; Boehringer Ingelheim France; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly O.; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Janssen; MSD; Ono Pharmaceutical
 
Haruki Kobayashi
No Relationships to Disclose
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma
Research Funding - AstraZeneca Japan; Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Toshiyuki Kozuki
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yuko Oya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly O.
Consulting or Advisory Role - Lilly O.
 
Hiroki Izumi
Honoraria - Bristol-Myers Squibb Japan; Chugai/Roche; Merck; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Takayuki Shiroyama
No Relationships to Disclose
 
Rie Tohnai
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Shota Kaname
Employment - Ono Pharmaceutical
 
Daiko Matsuoka
Employment - Eisai
 
Yohei Otake
Employment - Eisai
 
Takao Takase
Employment - Eisai
 
Taro Semba
Employment - Eisai
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly O.; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly O.; Merck; MSD; Pfizer; Taiho Pharmaceutical; Takeda